Drug:
Reaction: MALIGNANT NEOPLASM PROGRESSION
20260101 - 20261231
No. 101 - 200
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 101 | 26538839 |
IN |
40 | 2 |
Lung adenocarcinoma, Malignant neoplasm progression, Metastases to central nervous system, Intracranial pressure increased, Vomiting, |
||||
CRIZOTINIB, |
||||
| 102 | 26538920 |
EU |
||
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 103 | 26539136 |
KR |
69 | 1 |
Malignant neoplasm progression, Off label use, |
||||
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE, |
||||
| 104 | 26539375 |
EU |
||
Malignant neoplasm progression, |
||||
TRIFLURIDINE AND TIPIRACIL, BEVACIZUMAB, |
||||
| 105 | 26540194 |
US |
2 | |
Meningioma, Malignant neoplasm progression, |
||||
MEDROXYPROGESTERONE ACETATE, |
||||
| 106 | 26540516 |
JP |
72 | 1 |
Hypercalcaemia, Malignant neoplasm progression, |
||||
NIVOLUMAB, |
||||
| 107 | 26541313 |
75 | 1 | |
Pericardial effusion, Malignant neoplasm progression, |
||||
CETUXIMAB, NIVOLUMAB, CARBOPLATIN, |
||||
| 108 | 26541349 |
EU |
||
Malignant neoplasm progression, |
||||
DURVALUMAB, |
||||
| 109 | 26541907 |
EU |
||
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 110 | 26531114 |
JP |
48 | 2 |
Death, Hypothyroidism, Malaise, Platelet count decreased, Malignant neoplasm progression, Platelet function test abnormal, |
||||
PEMBROLIZUMAB, LENVATINIB, LENVATINIB, |
||||
| 111 | 26531183 |
VN |
67 | 1 |
Malignant neoplasm progression, |
||||
ENZALUTAMIDE, ENZALUTAMIDE, ZOLEDRONIC ACID, ZOLEDRONIC ACID, |
||||
| 112 | 26531584 |
EU |
||
Malignant neoplasm progression, |
||||
DURVALUMAB, |
||||
| 113 | 26531586 |
JP |
82 | 1 |
Malignant neoplasm progression, Bladder cancer, |
||||
ENFORTUMAB VEDOTIN, |
||||
| 114 | 26531785 |
US |
78 | 1 |
Red blood cell transfusion, Platelet count decreased, Malignant neoplasm progression, Biopsy bone marrow, Inappropriate schedule of product administration, Fatigue, Neck pain, |
||||
CEDAZURIDINE AND DECITABINE, CEDAZURIDINE AND DECITABINE, ACYCLOVIR, LORATADINE, LORATADINE TABLET, IRBESARTAN, LOSARTAN POTASSIUM, LOSARTAN, POLYETHYLENE GLYCOL 3350, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, STANDARDIZED SENNA CONCENTRATE AND DOCUSATE SODIUM, ACETAMINOPHEN, ERGOCALCIFEROL, |
||||
| 115 | 26532376 |
EU |
83 | 2 |
Polyneuropathy, Malignant neoplasm progression, Off label use, |
||||
ENFORTUMAB VEDOTIN, PEMBROLIZUMAB, |
||||
| 116 | 26532552 |
EU |
64 | 2 |
Malignant neoplasm progression, Radiotherapy, Immune-mediated hepatitis, |
||||
CARBOPLATIN, CARBOPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), PEMBROLIZUMAB, BEVACIZUMAB, |
||||
| 117 | 26533563 |
EU |
80 | 2 |
Death, Diffuse large B-cell lymphoma, Malignant neoplasm progression, Hypoalbuminaemia, |
||||
RITUXIMAB, POLATUZUMAB VEDOTIN, GLOFITAMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PREDNISONE, BENDAMUSTINE HCL, OXALIPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, |
||||
| 118 | 26534750 |
IN |
56 | 2 |
Multiple organ dysfunction syndrome, Condition aggravated, Malignant neoplasm progression, |
||||
IRINOTECAN HYDROCHLORIDE, |
||||
| 119 | 26534888 |
IL |
1 | |
Malignant neoplasm progression, Urinary retention, Constipation, Blood bilirubin increased, Weight decreased, Asthenia, |
||||
TRIFLURIDINE AND TIPIRACIL, TRIFLURIDINE AND TIPIRACIL, |
||||
| 120 | 26534954 |
EU |
66 | 1 |
Escherichia infection, Klebsiella infection, Pseudomonas infection, Enterococcal infection, Decubitus ulcer, Pleural effusion, Malignant neoplasm progression, |
||||
PIRTOBRUTINIB, PIRTOBRUTINIB, AMLODIPINE, BISOPROLOL FUMARATE, |
||||
| 121 | 26535175 |
EU |
50 | 2 |
Therapy partial responder, Metastases to liver, Lumbar vertebral fracture, Metastases to bone, Malignant neoplasm progression, Hormone receptor positive HER2 negative breast cancer, Spinal pain, Muscular weakness, Gait disturbance, Thrombocytosis, Anaemia, Resorption bone increased, Hypercalcaemia, Blood alkaline phosphatase increased, |
||||
RIBOCICLIB, LETROZOLE, LETROZOLE TABLETS, ZOLEDRONIC ACID, ZOLEDRONIC ACID, BUPRENORPHINE, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 122 | 26535294 |
US |
79 | 1 |
Lung neoplasm malignant, Malignant neoplasm progression, |
||||
LORLATINIB, CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, |
||||
| 123 | 26535397 |
74 | 2 | |
Neuropathy peripheral, Malignant neoplasm progression, |
||||
RAMUCIRUMAB, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), |
||||
| 124 | 26526946 |
EU |
32 | 2 |
Malignant neoplasm progression, |
||||
OLAPARIB, PEMBROLIZUMAB, CARBOPLATIN, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), |
||||
| 125 | 26527108 |
US |
2 | |
Malignant neoplasm progression, |
||||
CAPIVASERTIB, ALBUTEROL SULFATE, ALBUTEROL, AMLODIPINE, CEPHALEXIN, CYCLOBENZAPRINE, HYDRALAZINE HYDROCHLORIDE, LISINOPRIL, MELATONIN, METOPROLOL TARTRATE, METOPROLOL, POLYETHYLENE GLYCOL 3350, CALCIUM CARBONATE, SIMETHICONE, NITROFURANTOIN, NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, PROCHLORPERAZINE, VITAMIN C, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ALPRAZOLAM, FULVESTRANT, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, SEMAGLUTIDE, |
||||
| 126 | 26527277 |
US |
89 | 1 |
Malignant neoplasm progression, Pain in extremity, Fatigue, |
||||
RIPRETINIB, |
||||
| 127 | 26527324 |
US |
75 | 2 |
Malignant neoplasm progression, Product use in unapproved indication, |
||||
RIPRETINIB, RIPRETINIB, |
||||
| 128 | 26527424 |
US |
49 | 1 |
Malignant neoplasm progression, Hydrocephalus, |
||||
NIVOLUMAB, IPILIMUMAB, ENCORAFENIB, BINIMETINIB, |
||||
| 129 | 26528078 |
JP |
75 | 1 |
Death, Decreased appetite, Fatigue, Nausea, Neutrophil count decreased, Diarrhoea, Rash, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, CISPLATIN, |
||||
| 130 | 26528082 |
JP |
75 | 1 |
Death, Decreased appetite, Fatigue, Nausea, Neutrophil count decreased, Platelet count decreased, Malignant neoplasm progression, Rash, Pruritus, |
||||
PEMBROLIZUMAB, CISPLATIN, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 131 | 26528083 |
JP |
54 | 1 |
Death, Decreased appetite, Fatigue, Nausea, Quality of life decreased, Blood creatinine increased, Malignant neoplasm progression, Paronychia, Neuropathy peripheral, |
||||
PEMBROLIZUMAB, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, CISPLATIN, |
||||
| 132 | 26528130 |
JP |
||
Malignant neoplasm progression, Adverse event, |
||||
DURVALUMAB, |
||||
| 133 | 26528171 |
EU |
62 | 1 |
Pericardial effusion, Malignant neoplasm progression, Pleural effusion, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, NIVOLUMAB, NIVOLUMAB, CARBOPLATIN, CARBOPLATIN, LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE ORAL, METOCLOPRAMIDE HYDROCHLORIDE, PEMETREXED DISODIUM, PEMETREXED DISODIUM, PEMETREXED DISODIUM, TAMSULOSIN HYDROCHLORIDE, APREPITANT, FOSAPREPITANT DIMEGLUMINE, CANDESARTAN CILEXETIL, |
||||
| 134 | 26528244 |
GB |
86 | 2 |
Death, Malignant neoplasm progression, Fatigue, Nausea, Constipation, Product use complaint, Wrong technique in product usage process, |
||||
ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, LANSOPRAZOLE, ELACESTRANT, ELACESTRANT, |
||||
| 135 | 26528666 |
US |
||
Malignant neoplasm progression, |
||||
SELPERCATINIB, |
||||
| 136 | 26529400 |
JP |
2 | |
Immune-mediated adverse reaction, Malignant neoplasm progression, Gastrointestinal disorder, Disease recurrence, |
||||
OLAPARIB, DURVALUMAB, |
||||
| 137 | 26529565 |
EU |
62 | 1 |
Pericardial effusion, Malignant neoplasm progression, Pleural effusion, |
||||
CARBOPLATIN, CARBOPLATIN, NIVOLUMAB, NIVOLUMAB, PEMETREXED DISODIUM, PEMETREXED DISODIUM, PEMETREXED DISODIUM, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, TAMSULOSIN HYDROCHLORIDE, CANDESARTAN CILEXETIL, APREPITANT, FOSAPREPITANT DIMEGLUMINE, METOCLOPRAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE ORAL, |
||||
| 138 | 26529827 |
EU |
1 | |
Malignant neoplasm progression, Hormone receptor positive HER2 negative breast cancer, |
||||
FULVESTRANT, FULVESTRANT, PALBOCICLIB, |
||||
| 139 | 26529854 |
EU |
72 | 2 |
Immune-mediated enterocolitis, Cutaneous vasculitis, Malignant neoplasm progression, Thrombocytopenia, Drug hypersensitivity, |
||||
PEMETREXED, PEMETREXED DISODIUM, NIVOLUMAB, IPILIMUMAB, CARBOPLATIN, |
||||
| 140 | 26530037 |
RU |
72 | 1 |
Pancreatic steatosis, Paraplegia, Metastases to bone, Malignant neoplasm progression, Deficiency of bile secretion, Hepatomegaly, |
||||
TRIPTORELIN PAMOATE, TRIPTORELIN PAMOATE, ENZALUTAMIDE, |
||||
| 141 | 26530056 |
EU |
75 | 2 |
Immune-mediated hypothyroidism, Malignant neoplasm progression, |
||||
PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, DOSTARLIMAB, DOSTARLIMAB, DOSTARLIMAB, |
||||
| 142 | 26530084 |
AR |
67 | 2 |
Metastases to liver, Urinary retention, Breast cancer metastatic, Malignant neoplasm progression, Hypotension, Red blood cell count abnormal, Bradykinesia, Platelet count abnormal, White blood cell count abnormal, Agitation, Abdominal distension, Fluid retention, Tumour marker increased, Asthenia, |
||||
FULVESTRANT, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, LOSARTAN POTASSIUM, LOSARTAN, |
||||
| 143 | 26530343 |
US |
56 | 2 |
Malignant neoplasm progression, Memory impairment, Constipation, |
||||
TUCATINIB, |
||||
| 144 | 26530421 |
CN |
61 | 1 |
Drug ineffective, Ductal adenocarcinoma of pancreas, Malignant neoplasm progression, Off label use, |
||||
DABRAFENIB, TRAMETINIB, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 145 | 26530562 |
US |
54 | 2 |
Malignant neoplasm progression, Bladder discomfort, Dysphagia, Nausea, Diarrhoea, Vomiting, |
||||
ABEMACICLIB, |
||||
| 146 | 26530564 |
2 | ||
Suicidal ideation, Malignant neoplasm progression, Drug ineffective, |
||||
ABEMACICLIB, |
||||
| 147 | 26530620 |
CA |
2 | |
Gastrointestinal neuroendocrine tumour, Malignant neoplasm progression, Nausea, Vomiting, Drug intolerance, Off label use, |
||||
LUTETIUM LU 177 DOTATATE, LUTETIUM LU 177 DOTATATE, LUTETIUM LU 177 DOTATATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, CAPECITABINE, CAPECITABINE, TEMOZOLOMIDE, TEMOZOLOMIDE, OCTREOTIDE ACETATE, OCTREOTIDE, |
||||
| 148 | 26531010 |
JP |
75 | |
Diffuse large B-cell lymphoma, Malignant neoplasm progression, |
||||
EPCORITAMAB-BYSP, |
||||
| 149 | 26531073 |
TR |
80 | 1 |
Malignant neoplasm progression, |
||||
ENZALUTAMIDE, ZOLEDRONIC ACID, |
||||
| 150 | 26522611 |
CA |
||
Malignant neoplasm progression, |
||||
OSIMERTINIB, AMIVANTAMAB-VMJW, |
||||
| 151 | 26522680 |
EU |
34 | |
Malignant neoplasm progression, |
||||
TRASTUZUMAB, TRASTUZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 152 | 26523168 |
EU |
33 | 1 |
Malignant neoplasm progression, |
||||
RITUXIMAB, RITUXIMAB, RITUXIMAB, CARBOPLATIN, CARBOPLATIN, IFOSFAMIDE, IFOSFAMIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, POLATUZUMAB VEDOTIN, POLATUZUMAB VEDOTIN, DOXORUBICIN, ETOPOSIDE, ETOPOSIDE, PREDNISONE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, ALLOPURINOL, MESNA, MESNA INJECTION, |
||||
| 153 | 26523305 |
US |
50 | 1 |
Malignant neoplasm progression, Dizziness, Nausea, |
||||
RIPRETINIB, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM CAPSULE, DELAYED RELEASE, ESOMEPRAZOLE MAGNESIUM DIHYDRATE, ESOMEPRAZOLE MAGNESIUM DELAYED RELEASE CAPSULES, |
||||
| 154 | 26523342 |
JP |
8 | 2 |
Malignant neoplasm progression, Immune-mediated hepatic disorder, Anaemia, Haemorrhagic ascites, Skin disorder, Pyrexia, |
||||
IPILIMUMAB, NIVOLUMAB, |
||||
| 155 | 26523346 |
US |
78 | 1 |
Malignant neoplasm progression, |
||||
RIPRETINIB, ALENDRONATE SODIUM, ANASTROZOLE, ANASTROZOLE TABLETS, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, FERROUS SULFATE, FLECAINIDE ACETATE TABLET, FLECAINIDE ACETATE, IMATINIB MESYLATE, IMATINIB, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, AFLIBERCEPT-AYYH, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ERGOCALCIFEROL, |
||||
| 156 | 26523450 |
GB |
69 | 2 |
Malignant neoplasm progression, Off label use, |
||||
CARBOPLATIN, PACLITAXEL, |
||||
| 157 | 26523566 |
EU |
59 | |
Death, Malignant neoplasm progression, |
||||
TEBENTAFUSP, |
||||
| 158 | 26523781 |
JP |
84 | 2 |
Chronic myeloid leukaemia, Malignant neoplasm progression, Drug ineffective, |
||||
IMATINIB MESYLATE, IMATINIB, |
||||
| 159 | 26523849 |
EU |
33 | 1 |
Diffuse large B-cell lymphoma stage IV, Malignant neoplasm progression, |
||||
PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, POLATUZUMAB VEDOTIN, POLATUZUMAB VEDOTIN, POLATUZUMAB VEDOTIN, POLATUZUMAB VEDOTIN, ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, RITUXIMAB, RITUXIMAB, RITUXIMAB, CARBOPLATIN, CARBOPLATIN, DOXORUBICIN, DOXORUBICIN, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, IFOSFAMIDE, IFOSFAMIDE, IFOSFAMIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, ALLOPURINOL, MESNA, MESNA INJECTION, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 160 | 26523949 |
GB |
1 | |
Prostate cancer, Malignant neoplasm progression, Dry mouth, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 161 | 26523954 |
GB |
||
Death, Neuropathy peripheral, Malignant neoplasm progression, Constipation, Nausea, |
||||
ELACESTRANT, |
||||
| 162 | 26524055 |
EU |
2 | |
Malignant neoplasm progression, Neuropathy peripheral, Infrequent bowel movements, Abdominal pain, Carbohydrate antigen 125 increased, Nausea, Decreased appetite, Flatulence, |
||||
BEVACIZUMAB, OLAPARIB, |
||||
| 163 | 26524144 |
EU |
64 | |
Immune-mediated hepatitis, Malignant neoplasm progression, Radiotherapy, |
||||
BEVACIZUMAB, PEMBROLIZUMAB, CARBOPLATIN, CARBOPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), |
||||
| 164 | 26524618 |
JP |
77 | 1 |
Malignant neoplasm progression, Hepatic function abnormal, |
||||
DURVALUMAB, TREMELIMUMAB, AMLODIPINE, CANDESARTAN, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, |
||||
| 165 | 26524621 |
US |
2 | |
Malignant neoplasm progression, Drug ineffective, |
||||
PEMBROLIZUMAB, LENVATINIB, FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 166 | 26524671 |
US |
68 | 1 |
Bile duct stone, Abdominal pain, Liver function test increased, Eye disorder, Metastases to eye, Malignant neoplasm progression, Gastroenteropancreatic neuroendocrine tumour disease, |
||||
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, INSULIN LISPRO, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, LISINOPRIL, LOSARTAN, SEMAGLUTIDE, ORAL SEMAGLUTIDE, EMPAGLIFLOZIN, CARBOXYMETHYLCELLULOSE SODIUM, GABAPENTIN, AMLODIPINE, LEVETIRACETAM, LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, |
||||
| 167 | 26524683 |
AU |
2 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, OSIMERTINIB, |
||||
| 168 | 26524779 |
65 | 1 | |
Pericardial effusion, Bone marrow failure, Cardiorenal syndrome, Hypertension, Malignant neoplasm progression, Enterococcal infection, Urinary tract infection, Thrombocytopenia, Anaemia, Thrombotic microangiopathy, |
||||
PACLITAXEL, FUROSEMIDE, |
||||
| 169 | 26525181 |
EU |
2 | |
Breast cancer, Renal failure, Metastases to liver, Malignant neoplasm progression, Metastases to bone, Hypercalcaemia, |
||||
PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), RIBOCICLIB, |
||||
| 170 | 26525474 |
CN |
1 | |
Malignant neoplasm progression, |
||||
TRIPTORELIN, ENZALUTAMIDE, LEUPROLIDE, GOSERELIN, GOSERELIN, |
||||
| 171 | 26525861 |
US |
38 | |
Malignant neoplasm progression, Off label use, |
||||
NIVOLUMAB, IPILIMUMAB, |
||||
| 172 | 26526158 |
SG |
39 | 2 |
Malignant neoplasm progression, Pneumonitis, |
||||
OXALIPLATIN, OXALIPLATIN, OXALIPLATIN, OXALIPLATIN, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, CAPECITABINE, CAPECITABINE, CAPECITABINE, CAPECITABINE, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 173 | 26526418 |
US |
1 | |
Malignant neoplasm progression, |
||||
CARBOPLATIN, GEMCITABINE HYDROCHLORIDE, |
||||
| 174 | 26526421 |
US |
70 | 1 |
Malignant neoplasm progression, |
||||
LORLATINIB, |
||||
| 175 | 26526426 |
US |
70 | 1 |
Prostate cancer metastatic, Malignant neoplasm progression, Metastases to bone, Metastases to lymph nodes, Metastases to neck, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 176 | 26526479 |
US |
72 | 2 |
Malignant neoplasm progression, Diarrhoea, |
||||
LENVATINIB, LENVATINIB, LENVATINIB, PEMBROLIZUMAB, |
||||
| 177 | 26522317 |
KR |
||
Malignant neoplasm progression, |
||||
ALECTINIB HYDROCHLORIDE, |
||||
| 178 | 26522321 |
CA |
2 | |
Malignant neoplasm progression, Ovarian cancer, Off label use, |
||||
LETROZOLE, LETROZOLE TABLETS, CITALOPRAM, CITALOPRAM HYDROBROMIDE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 179 | 26521470 |
JP |
87 | 2 |
Rash pruritic, Malignant neoplasm progression, |
||||
TREMELIMUMAB, DURVALUMAB, |
||||
| 180 | 26521727 |
IN |
79 | 1 |
Malignant neoplasm progression, |
||||
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE, |
||||
| 181 | 26517058 |
EU |
82 | 1 |
Dizziness postural, Acute coronary syndrome, Myocarditis, Seizure, Fall, Oxygen saturation decreased, Bradycardia, Cardiovascular disorder, Malignant neoplasm progression, |
||||
NIVOLUMAB, NIVOLUMAB, NIVOLUMAB, IPILIMUMAB, IPILIMUMAB, |
||||
| 182 | 26517080 |
CH |
||
Malignant neoplasm progression, |
||||
OSIMERTINIB, OSIMERTINIB, TEPOTINIB HYDROCHLORIDE, |
||||
| 183 | 26517684 |
US |
63 | 1 |
Malignant neoplasm progression, Sensitive skin, Paraesthesia, Drug ineffective, |
||||
RIPRETINIB, ACARBOSE, ALBUTEROL SULFATE, AMLODIPINE, FERROUS SULFATE, FUROSEMIDE, EMPAGLIFLOZIN, FINERENONE, LISINOPRIL, LORATADINE, LORATADINE ORAL, PREDNISONE, SODIUM BICARBONATE, SODIUM BICARBONATE INJECTION,, SODIUM POLYSTYRENE SULFONATE, |
||||
| 184 | 26518008 |
EU |
32 | 1 |
Hepatic failure, COVID-19, Febrile neutropenia, Upper gastrointestinal haemorrhage, Malignant neoplasm progression, Leukopenia, Anaemia, Off label use, |
||||
CABOZANTINIB, CABOZANTINIB, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), |
||||
| 185 | 26518196 |
AU |
65 | 1 |
Neuropathy peripheral, Pulmonary sepsis, Malignant neoplasm progression, Pneumonitis, Diarrhoea, Steroid diabetes, Off label use, |
||||
NIVOLUMAB, IPILIMUMAB, |
||||
| 186 | 26518456 |
JP |
79 | 2 |
Malignant neoplasm progression, Pain of skin, Hypertension, Stomatitis, Dysphonia, Thrombocytopenia, Blood thyroid stimulating hormone increased, Arthralgia, Somnolence, Rash, Decreased appetite, Pyrexia, Malaise, Nausea, Diarrhoea, Vomiting, Thrombocytopenia, Hypothyroidism, Myocarditis, Inappropriate schedule of product administration, Inappropriate schedule of product administration, Inappropriate schedule of product administration, Inappropriate schedule of product administration, Inappropriate schedule of product administration, Inappropriate schedule of product administration, Inappropriate schedule of product administration, Inappropriate schedule of product administration, Inappropriate schedule of product administration, Inappropriate schedule of product administration, Inappropriate schedule of product administration, Inappropriate schedule of product administration, Inappropriate schedule of product administration, Inappropriate schedule of product administration, Inappropriate schedule of product administration, Inappropriate schedule of product administration, Inappropriate schedule of product administration, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, LENVATINIB, LENVATINIB, LENVATINIB, LENVATINIB, |
||||
| 187 | 26518498 |
TH |
64 | 2 |
Malignant neoplasm progression, Pulmonary oedema, Inappropriate schedule of product administration, Therapy change, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 188 | 26518647 |
KR |
2 | |
Malignant neoplasm progression, Bladder catheterisation, Enema administration, Drain placement, Endotracheal intubation, Mechanical ventilation, Platelet transfusion, Drain placement, Enteral nutrition, Airway secretion clearance therapy, Drain placement, Continuous haemodiafiltration, Airway secretion clearance therapy, Oxygen therapy, Gastrointestinal tube insertion, Oxygen therapy, Red blood cell transfusion, Clotting factor transfusion, Product use in unapproved indication, Herpes zoster, Platelet transfusion, Mechanical ventilation, Abscess drainage, Continuous haemodiafiltration, Respiratory failure, Hospitalisation, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 189 | 26519491 |
US |
1 | |
Ductal adenocarcinoma of pancreas, Malignant neoplasm progression, Product use in unapproved indication, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CAPECITABINE, |
||||
| 190 | 26519715 |
EU |
2 | |
Malignant neoplasm progression, Neuropathy peripheral, Metastases to pleura, Metastases to retroperitoneum, Metastases to peritoneum, |
||||
BEVACIZUMAB, OLAPARIB, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, METOCLOPRAMIDE HYDROCHLORIDE, |
||||
| 191 | 26519898 |
EU |
79 | |
Sinus node dysfunction, Hypokalaemia, Hypokalaemia, Colitis, Malignant neoplasm progression, Cardiotoxicity, Diarrhoea, Diarrhoea, Dysphagia, Hyponatraemia, Dehydration, Tachycardia, |
||||
TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 192 | 26520052 |
PH |
59 | 1 |
Pulmonary embolism, Malignant neoplasm progression, Neurofibrosarcoma, Weight decreased, Decreased appetite, Fatigue, |
||||
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, |
||||
| 193 | 26520062 |
EU |
64 | 2 |
Radiotherapy, Malignant neoplasm progression, Immune-mediated hepatitis, |
||||
CARBOPLATIN, CARBOPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, PEMBROLIZUMAB, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), BEVACIZUMAB, |
||||
| 194 | 26520226 |
JP |
67 | 2 |
Death, Thyroid disorder, Malignant neoplasm progression, Drug hypersensitivity, |
||||
PEMBROLIZUMAB, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), LENVATINIB, CARBOPLATIN, |
||||
| 195 | 26520231 |
HK |
57 | 1 |
Malignant neoplasm progression, Metastases to central nervous system, Treatment failure, |
||||
OSIMERTINIB, |
||||
| 196 | 26520439 |
UZ |
1 | |
Death, Chronic myeloid leukaemia, Malignant neoplasm progression, Product dose omission issue, |
||||
| 197 | 26520465 |
EU |
33 | 2 |
Intermenstrual bleeding, Cough, Neutropenia, Malignant neoplasm progression, |
||||
BEVACIZUMAB, TRIFLURIDINE AND TIPIRACIL, |
||||
| 198 | 26520466 |
US |
1 | |
Portal vein thrombosis, Gallbladder adenocarcinoma, Malignant neoplasm progression, Off label use, |
||||
GEMCITABINE HYDROCHLORIDE, CISPLATIN, DURVALUMAB, |
||||
| 199 | 26520568 |
UA |
1 | |
Neutropenia, Malignant neoplasm progression, Nausea, |
||||
TRIFLURIDINE AND TIPIRACIL, BEVACIZUMAB, |
||||
| 200 | 26520722 |
EU |
56 | 1 |
Hyperthyroidism, Peripheral sensory neuropathy, Hepatitis, Malignant neoplasm progression, Aphthous ulcer, Agranulocytosis, |
||||
IPILIMUMAB, NIVOLUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28